Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $43.71

Key Points

• Arrowhead Pharmaceuticals has received a consensus rating of "Moderate Buy" from nine analysts, with an average price target of $43.71.
• The company reported an impressive $2.75 EPS for the last quarter, exceeding analysts' estimates of ($0.06), and generated revenue of $542.71 million.
• The stock currently trades at $15.92, reflecting a 1.7% decrease, with a market capitalization of $2.20 billion.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine analysts that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $43.71.

Several equities research analysts have recently issued reports on ARWR shares. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Citigroup reduced their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Wall Street Zen cut Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Finally, TD Cowen raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in shares of Arrowhead Pharmaceuticals by 297.6% during the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,628 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $49,000. Nisa Investment Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals by 75.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock valued at $48,000 after buying an additional 1,308 shares during the period. CWM LLC boosted its position in shares of Arrowhead Pharmaceuticals by 134.3% during the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after buying an additional 2,523 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Arrowhead Pharmaceuticals by 29.5% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock valued at $84,000 after buying an additional 1,214 shares during the period. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR traded up $0.13 on Wednesday, reaching $15.93. 1,519,077 shares of the company's stock traded hands, compared to its average volume of 1,894,845. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 0.31. The stock has a 50-day simple moving average of $16.41 and a 200-day simple moving average of $16.11. The firm has a market cap of $2.20 billion, a PE ratio of -11.38, a P/E/G ratio of 18.47 and a beta of 0.93. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $27.34.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same period in the prior year, the business earned ($1.02) earnings per share. Equities research analysts forecast that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.